Publication | Closed Access

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer

UrologyOncologyMedicinePharmacotherapyAnti-cancer AgentProstatic DiseasePharmacologyDrug Sequence ChoicesDrug DiscoveryDrug Resistance